

YOU'RE
INVITED!

A LIVE PRESENTATION

A Novel Inhaled Maintenance Treatment of COPD

PROGRAM HIGHLIGHTS

- In-depth discussion on Ohtuvayre™ and its utility for patients with COPD
- Insights from leading experts in respiratory care
- Interactive Q&A session



Presented by:
Azmi Draw, MD, FCCP
Lung and Sleep Specialists
New Albany, IN

When:
Tuesday, May 19, 2026
6:30 PM EDT

Hosted by:
Lyndsay Arbuckle
+1 (231) 492-6668
lyndsay.arbuckle@veronapharma.com

Where:
Stone Creek
1424 W Stones Crossing Road
Greenwood, IN 46143

Please RSVP

<https://veronameetings.com/reg/Ohtuvayre-OLO250333>



This program is intended for Healthcare Professionals with an appropriate specialty and select healthcare staff only.
This is a non-CME program sponsored by Verona Pharma.

Verona Pharma is a subsidiary of Merck & Co., Inc. Rahway, NJ, USA. When applicable, Verona Pharma will use registration information to facilitate compliance with all federal and state laws requiring disclosure of remuneration attributable to healthcare professionals attending the event. Verona Pharma will aggregate event expenses and apportion appropriately among participants.

References: 1. Ohtuvayre® (ensifentrine). Prescribing Information. Raleigh, NC: Verona Pharma plc; 2024. 2. Anzueto A, Barjaktarevic IZ, Siler TM, et al. Enifentrine, a novel phosphodiesterase 3 and 4 inhibitor of the treatment of chronic obstructive pulmonary disease: randomized, double-blind, placebo-controlled, multicenter phase III trials (the ENHANCE Trials). *Am J Respir Crit Care Med*.



©2026 Verona Pharma plc. All rights reserved.

Verona Pharma, Ohtuvayre, and the Verona Pharma and Ohtuvayre logos are all trademarks of Verona Pharma plc.

US-OHT-00034 1/2026